<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	>
<channel>
	<title>Comments on: A New Headache For Bayer: A Patent Loss</title>
	<atom:link href="http://www.pharmalot.com/2008/03/a-new-headache-for-bayer-a-patent-loss/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.pharmalot.com/2008/03/a-new-headache-for-bayer-a-patent-loss/</link>
	<description>News, Comment and Conversation</description>
	<pubDate>Mon, 12 May 2008 06:35:09 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.5.1</generator>
		<item>
		<title>By: A New Headache For Bayer: A Patent Loss &#183; One Looking</title>
		<link>http://www.pharmalot.com/2008/03/a-new-headache-for-bayer-a-patent-loss/#comment-188499</link>
		<dc:creator>A New Headache For Bayer: A Patent Loss &#183; One Looking</dc:creator>
		<pubDate>Tue, 04 Mar 2008 13:19:07 +0000</pubDate>
		<guid isPermaLink="false">http://www.pharmalot.com/2008/03/a-new-headache-for-bayer-a-patent-loss/#comment-188499</guid>
		<description>[...] culturekitchen &#124; fresh dissent served daily wrote an interesting post today onHere&#8217;s a quick excerpt You know the old saying: Just when you think things can’t get worse…they do. The latest malady confronting the drugmaker is ruling by a federal judge that invalidated a patent on its Yasmin contraceptive pill, which gives Barr Laboratories a chance to sell a generic before the patent expires in 2020. For now, Bayer retains exclusive distribution rights in the US until March 2009, just one year from now. The news sent Bayer stock tumbling more than 5 percent, because Yasmin generated nearly $49 [...]</description>
		<content:encoded><![CDATA[<p>[...] culturekitchen | fresh dissent served daily wrote an interesting post today onHere&#8217;s a quick excerpt You know the old saying: Just when you think things can’t get worse…they do. The latest malady confronting the drugmaker is ruling by a federal judge that invalidated a patent on its Yasmin contraceptive pill, which gives Barr Laboratories a chance to sell a generic before the patent expires in 2020. For now, Bayer retains exclusive distribution rights in the US until March 2009, just one year from now. The news sent Bayer stock tumbling more than 5 percent, because Yasmin generated nearly $49 [...]</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: A New Headache For Bayer: A Patent Loss</title>
		<link>http://www.pharmalot.com/2008/03/a-new-headache-for-bayer-a-patent-loss/#comment-188495</link>
		<dc:creator>A New Headache For Bayer: A Patent Loss</dc:creator>
		<pubDate>Tue, 04 Mar 2008 13:16:43 +0000</pubDate>
		<guid isPermaLink="false">http://www.pharmalot.com/2008/03/a-new-headache-for-bayer-a-patent-loss/#comment-188495</guid>
		<description>[...] culturekitchen &#124; fresh dissent served daily wrote an interesting post today onHere&#8217;s a quick excerpt You know the old saying: Just when you think things can’t get worse…they do. The latest malady confronting the drugmaker is ruling by a federal judge that invalidated a patent on its Yasmin contraceptive pill, which gives Barr Laboratories a chance to sell a generic before the patent expires in 2020. For now, Bayer retains exclusive distribution rights in the US until March 2009, just one year from now. The news sent Bayer stock tumbling more than 5 percent, because Yasmin generated nearly $49 [...]</description>
		<content:encoded><![CDATA[<p>[...] culturekitchen | fresh dissent served daily wrote an interesting post today onHere&#8217;s a quick excerpt You know the old saying: Just when you think things can’t get worse…they do. The latest malady confronting the drugmaker is ruling by a federal judge that invalidated a patent on its Yasmin contraceptive pill, which gives Barr Laboratories a chance to sell a generic before the patent expires in 2020. For now, Bayer retains exclusive distribution rights in the US until March 2009, just one year from now. The news sent Bayer stock tumbling more than 5 percent, because Yasmin generated nearly $49 [...]</p>
]]></content:encoded>
	</item>
</channel>
</rss>
